Drugs / JTT-861
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06017609 | Dec 2023 → May 2026 | heart failure | Akros Pharma Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JTT-861 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06017609 ↗ |
| Route | Oral | “JTT-861 Capsules Dose 1 orally once daily for 12 weeks” NCT06017609 ↗ |